CV2CoV, an enhanced mRNA based SARS-CoV-2 vaccine candidate supports higher protein expression and improved immunogenicity in rats

Nicole Roth¹, Donata Hoffmann², Björn Corleis³, Anca Dorhoi³, Martin Beer², Moritz Thran¹, Andreas Thess¹, Stefan O. Mueller¹, Benjamin Petsch¹ and Susanne Rauch¹*

Affiliations:
¹ CureVac AG, Tübingen, Germany
² Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
³ Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany

* Corresponding author: Email: susanne.rauch@curevac.com

Abstract:
More than a year after the start of the SARS-CoV-2 pandemic, multiple first generation vaccines are approved and available for vaccination. Still, many challenges remain. The ongoing vaccination programs across the globe suffer from insufficient vaccine supply. The virus is adapting to the human host and more transmissible variants are circulating that are neutralised less efficiently by antibodies raised against ancestral virus. Here we describe CV2CoV, a second generation mRNA vaccine developed for enhanced protein expression and immunogenicity. CV2CoV supports increased levels of protein expression in cell culture compared to our clinical candidate CVnCoV. Vaccination with CV2CoV induces high levels of virus neutralising antibodies with accelerated kinetics in rats. Robust antibody responses are reflected in significant cross-neutralisation of circulating SARS-CoV-2 variants of concern, i.e. B.1.1.7 and B.1.351. Together, these results underline the value of CV2CoV as next generation SARS-CoV-2 mRNA vaccine.

Introduction

The ongoing COVID19 pandemic creates a worldwide need for fast development of vaccines. By April 2021, thirteen vaccines against SARS-CoV-2 have received authorisation by at least one national regulatory authority ¹ and a total of ninety-three vaccine candidates are currently in clinical development ². However, the emergence of more transmissible and virulent SARS-CoV-2 variants
potentially able to escape pre-existing immunity highlights the need for continuous improvement and adaptation of vaccines. mRNA vaccines represent a promising technology to meet this need: they are based on a highly versatile, adaptable platform technology whose efficacy as a vaccine against SARS-CoV-2 has been demonstrated resulting in authorized vaccines.

CureVac’s mRNA technology termed RNActive® is based on non-chemically modified, sequence engineered mRNA. This technology supports high protein expression and moderate activation of innate immune responses. RNActive® vaccines have shown promise in the context of different infectious diseases in both preclinical and clinical studies and provide the basis for the CVnCoV, a lipid nanoparticle (LNP) formulated mRNA vaccine against SARS-CoV-2 encoding for full length Spike (S) protein. Preclinical results have demonstrated CVnCoV’s ability to induce robust cellular and humoral immune responses as well as protective efficacy in rodents and non-human primates (NHPs). Phase 1 clinical trials have established CVnCoV’s safety and tolerability. Vaccination with 12 µg of CVnCoV resulted in full seroconversion two weeks post injection of the second dose and showed comparable virus neutralising antibody titres to convalescent sera.

CVnCoV is currently tested in phase 2b/3 studies that investigate the efficacy, safety, and immunogenicity. Here we show the results of our second generation SARS-CoV-2 vaccine, CV2CoV. This vaccine was developed to increase vaccine efficacy, thereby setting the stage to tackle future challenges of the SARS-CoV-2 pandemic. These will likely include the requirement for high vaccine-induced immune responses to compensate for reduced virus neutralisation responses and efficacy of different variants. In addition, emerging immune escape variants might necessitate multivalent vaccines, in which each component needs to be efficacious at a lower dose. Beyond this, dose sparing supported by a more immunogenic vaccine might facilitate providing more doses for a worldwide need.

CVnCoV and second generation CV2CoV are sequence optimized, capped, chemically unmodified mRNA-based vaccines that are encapsulated using the same lipid nanoparticle (LNP) technology. Both encode full-length SARS-CoV-2 S protein with pre-fusion stabilising K986P and V987P mutations. The vaccines differ in their non-structural elements flanking the open reading frame (ORF), i.e. the 5’ and 3’ untranslated regions (UTRs) and the 3’ tail. These changes were introduced to improve intracellular RNA stability and translation, aimed to increase and prolong protein expression and thereby improve immunogenicity.
Here we show that the mRNA component in CV2CoV indeed supports higher levels of protein expression in cell culture. Vaccination with CV2Cov in a rat model induces robust levels of humoral responses that are detectable upon a single injection and that cross-react with different SARS-CoV-2 variants.

Results and discussion

Despite promising results of CVnCoV in both preclinical models and early clinical evaluations, we have continued the development of our mRNA technology with the aim to create a vaccine against SARS-CoV-2 with enhanced immunogenicity. Here we present results of our preclinical SARS-CoV-2 candidate vaccine CV2CoV that features changes in the non-coding regions compared to our clinical candidate CVnCoV. Flow cytometry based analysis of protein expression levels of the mRNA components in CV2CoV and CVnCoV in HeLa cells demonstrated a substantial increase of protein expression upon transfection with CV2CoV compared to CVnCoV mRNA. This effect was evident in both total and cell surface expression of the S protein. CV2CoV mRNA displayed a 3.3 fold increase in intracellular and a 1.8 fold increase in cell surface expression compared to CVnCoV mRNA (Figure 1).

We next characterized the immunogenicity of the second generation vaccine CV2CoV in a small animal model. Wistar rats were vaccinated twice (d0, d21) with five different doses ranging from 0.5 µg – 40 µg. NaCl vaccinated animals served as negative control. Rats vaccinated with CV2CoV at 0.5 µg, 2 µg or 8 µg elicited a strong dose dependent binding antibody response directed against the S receptor binding domain (RBD). High values of RBD reactive antibodies without a clear dose response was detectable upon vaccination with 20 µg and 40 µg CV2CoV (Figure 2). RBD binding antibodies developed rapidly and were detectable two weeks after a single vaccination in all dose groups (Figure 2A). Both IgG1 and IgG2a titres increased over time and a clear boost effect was detectable upon second vaccination (Figure 2B and 2C).

Induction of virus neutralising titres (VNTs) in rat sera were assessed in a cytopathic effect (CPE)-based assay with homologue wild-type SARS-CoV-2 (Figure 3). CV2CoV induced significant, dose dependent levels of VNTs two weeks after a single vaccination in all animals vaccinated with a dose of 2 µg or higher (Figure 3A). On day 14, CV2CoV induced titres ranging from 1:42 in the 2 µg group to 1:193 in the 40 µg group. VNTs increased over time and a clear boost effect was detectable (Figure 3B and 3C). The second vaccination led to significant increase in VNTs in all dose groups except for
two animals in the 0.5 µg group. On d42, VNTs in animals that had received ≥2 µg exceeded the upper range of detection in the assay, i.e. a dilution of 1:5120 (Figure 3C).

In summary, vaccination with CV2CoV induced high, dose dependent levels of RBD binding and virus neutralising antibodies in outbred rats. Antibody responses were detectable in doses as low as 0.5 µg and doses of ≥2 µg resulted in robust antibody levels. Importantly, a single vaccination of ≥2µg was sufficient to induce VNT two weeks post injection. In comparison, preclinical studies in rats, hamsters and NHPs have shown that two vaccination of CVnCoV are required to induce significant levels of VNTs, providing proof for the enhanced characteristics of CV2CoV.

CV2CoV's ability to induce robust levels of neutralising antibodies was highlighted by its ability to cross neutralise three SARS-CoV-2 variants. VNTs in the day 42 sera against heterologous SARS-CoV-2 variants, i.e. B.1.1.298, B.1.1.7 and B.1.351 originating from Denmark, the UK and South Africa, respectively, compared to ancestral SARS-CoV-2 (B.1) were analysed. Again, a comparable CPE based assay system based on wild-type SARS-CoV-2 that was employed. CV2CoV induced high levels of VNTs against all tested SARS-CoV-2 variants in a dose dependent manner (Figure 4). In the 8 µg dose group, CV2CoV induced median titres of 1:2438 (B.1. (Figure 4A)), 1:4096 (B.1.1.298 (Figure 4B)), 1:1935 (B1.1.7 (Figure 4C)) and 1:806 (B.1.351 (Figure 4D)). Overall, sera from CV2CoV vaccinated animals were able to neutralise B.1.1.298 without detectable decrease. A reduction of VNTs were measured against B.1.1.7 and B.1.351, where a median decrease across all dose groups of 1.3 (B.1.1.7) and 4.0 fold (B.1.351) was detected. These values are comparable to or better than previously observed cross-neutralisation.

In summary, CV2CoV represents a highly promising second generation vaccine with improved characteristics, including accelerated induction of VNTs two weeks after the first vaccination. Its ability to induce high levels of antibodies against SARS-CoV-2 at low doses supports a scenario in which vaccination with CV2CoV allows dose sparing that might be able to contribute to reduce worldwide vaccine shortage. Moreover, this characteristic allows CV2CoV's application in the context of multivalent vaccines that might become necessary as the virus mutates further. Overall, CV2CoV represents a highly promising candidate for further clinical development to help meet some of the challenges of the SARS-CoV-2 pandemic.
Material and Methods

mRNA vaccines

The mRNA vaccines are based on the RNActive® platform (claimed and described in e.g. WO2002098443 and WO2012019780) and are comprised of a 5’ cap1 structure, a GC-enriched open reading frame (ORF), 3’ UTR, a vector-encoded polyA stretch and does not include chemically modified nucleosides. CVnCoV contains parts of the 3’ UTR of the Homo sapiens alpha haemoglobin gene as 3’ UTR followed by a polyA stretch, a C30 stretch and a histone stem loop. CV2CoV further comprises a 5’ UTR from the human hydroxysteroid 17-beta dehydrogenase 4 gene (HSD17B4) and a 3’ UTR from human proteasome 20S subunit beta 3 gene (PSMB3) followed by a histone stem loop and a polyA stretch. Lipid nanoparticle (LNP)-encapsulation of mRNA was performed by Acuitas Therapeutics (Vancouver, Canada). The LNPs used in this study are particles of ionizable amino lipid, phospholipid, cholesterol and a PEGylated lipid. The mRNA encoded protein is based on the spike glycoprotein of SARS-CoV-2 NCBI Reference Sequence NC_045512.2, GenBank accession number YP_009724390.1 and encodes for full length S featuring K986P and V987P mutations.

In vitro protein expression

For detection of mRNA expression in cell culture, HeLa cells were seeded in 6-well plates at a density of 400,000 cells/well. 24h later, cells were transfected with 2µg of mRNA per well via Lipofectamine. For this, RNAs were complexed with Lipofectamine 2000 (Life Technologies) at a ratio of 1:1.5 and transfected into cells according to manufacturer’s protocol. Protein expression was assessed 24h post transfection. For FACS analysis, cells were fixed and analysed with intact (surface staining) or permeabilised plasma membranes via treatment with Perm/Wash buffer (BD Biosciences, Cat. 554723) (intracellular staining). Specific S protein expression was assessed via staining with Human anti SARS CoV S antibody (CR3022) (Creative Biolabs, Cat. MRO-1214LC) followed by goat anti-human IgG F(ab’)2 fragment PE antibody (Immuno Research, Cat. 109-116-097) in a BD FACS Canto II cell analyzer and the FlowJo 10 software.

Animals

Female and male rats (Wistar, 7-8 weeks of age) were provided and handled by Preclinics Gesellschaft für präklinische Forschung mbH, (Potsdam, Germany). The animal study was conducted in...
accordance with German laws and guidelines for animal protection and appropriate local and national approvals.

**Immunisations**

Animals were injected intramuscularly (IM) into the Musculus Gastrocnemius with different doses from 0.5-40 µg LNP-formulated SARS-CoV-2 mRNA (CV2CoV) or NaCl as negative control.

**Antibody analysis**

SARS-CoV-2 Spike RBD protein specific IgG1 and IgG2a binding antibodies were detected via ELISA. Plates were coated with 1µg/ml of SARS-CoV-2 (2019-nCoV) Spike RBD-His (Sino Biologicals, Cat. 40592-V08B) for 4-5h at 37°C. Plates were blocked overnight in 1% BSA, washed and incubated with serum for 2h at room temperature. For detection, rat sera were incubated with biotin mouse anti-rat IgG1 (Biolegend, Cat. 407404) or biotin mouse anti-rat IgG2a (Biolegend, Cat. 407504), followed by incubation with HRP-Streptavidin (BD, Cat: 554066). Detection of specific signals was performed in a BioTek SynergyHTX plate reader, with excitation 530/25, emission detection 590/35 and a sensitivity of 45.

For the analysis of virus neutralising titres of rat sera shown in Figure 2, serial dilutions of heat-inactivated sera (56°C for 30 min) tested in duplicates with a starting dilution of 1:10 followed by 1:2 serial dilutions were incubated with 100 TCID50 of wild type SARS-CoV-2 (strain 2019-nCov/Italy-INMI1) for 1 hour at 37°C. Every plate contained a dedicated row (8 wells) for cell control which contains only cells and medium, and a dedicated row of virus control which contain only cells and virus. Infectious virus was quantified upon incubation of 100 µl of virus-serum mixture with a confluent layer of Vero E6 cells (ATCC, Cat.1586) followed by incubation for 3 days at 37°C and microscopical scoring for CPE formation. A back titration was performed for each run in order to verify the correct range of TCID50 of the working virus solution. VN titres were calculated according to the method described by Reed & Muench. If no neutralisation was observed (MNt <10), an arbitrary value of 5 was reported. Analyses were carried out at VisMederi srl (Siena, Italy).

For the analysis of VNTs against the different SARS-CoV-2 isolates shown in Figure 3, sera were pre-diluted 1:16 with DMEM. Three times 100 µl, representing three technical replicates, of this pre-dilution were transferred into a 96 well plate. A log2 dilution was conducted by passaging 50 µl of the serum dilution in 50 µl DMEM, leaving 50 µl of sera dilution in each well. Subsequently 50 µl of the respective
SARS-CoV-2 (B.1.1.298, B.1.1.7 or B.1.351) virus dilution (100 TCID50/well) was added to each well and incubated for 1 hour at 37 °C. Lastly, 100 µl of trypsinated VeroE6 cells (cells of one confluent TC175 flask per 100 ml) in DMEM with 1 % penicillin/streptomycin supplementation was added to each well. After 72 hours incubation at 37 °C, the wells were evaluated by light microscopy. A serum dilution was counted as neutralising in the case no specific CPE was visible. The virus titre was confirmed by virus titration, positive and negative serum samples were included. Analysis were carried out at Friedrich-Loeffler-Institut (Greifswald, Germany).
Figure 1: CV2CoV enhances protein expression. Flow cytometric analysis using an S-specific antibody either with or without membrane permeabilisation allowing detection of total (intracellular) or cell surface bound (cell surface) S protein. Geometric mean fluorescence intensity (GMFI) of transfected HeLa cells are expressed as mean + standard deviation (SD) of duplicate samples.
Figure 2: CV2CoV triggers high levels of binding antibody responses in rats. Female and male Wistar rats (n=6/group) were vaccinated IM on day 0 and d21 with five different doses ranging from 0.5 µg – 40 µg of CV2CoV. Wistar rats (n=4) vaccinated with 0.9% NaCl (Buffer) on day 0 and day 21 served as negative control. S<sub>RRD</sub> protein specific binding antibodies, displayed as endpoint titres for IgG1 and IgG2a in serum upon one vaccination ((A) day 14 and (B) day 21) or two vaccinations ((C) day 42). Each dot represents an individual animal, bars depict the median.

Figure 3: CV2CoV induces high titres of virus neutralising antibodies against SARS-CoV-2 in rats. Female and male Wistar rats (n=6/group) were vaccinated IM with five different doses ranging from 0.5 µg – 40 µg of CV2CoV on day 0 and day 21. Animals (n=4) vaccinated with NaCl (Buffer) served as negative controls. CPE-based VNTs in serum samples taken on day 14, day 21 and day 42 were analysed. Each dot represents an individual animal, bars depict the median.
Figure 4: CV2CoV induces high titres of cross neutralising antibodies against SARS-CoV-2 variants in rats. Female and male Wistar rats (n=6/group) were vaccinated IM with five different doses ranging from 0.5 µg – 40 µg of CV2CoV on day 0 and day 21. Animals (n=4) vaccinated with NaCl (Buffer) served as negative controls. CPE-based VNTs in serum samples taken on day 42 against different SARS-CoV-2 variants were analysed as indicated. Each dot represents an individual animal, bars depict the median.


